Corporate News

2025

2023

18 December
Holding(s) in Company
04 December
Scientific Educational Programme Expanded
28 November
Holding(s) in Company
23 November
Half-Year Report
22 November
Holding(s) in Company
20 November
Holding(s) in Company
17 November
Holding(s) in Company
17 November
Holding(s) in Company
10 November
Warrant Expiry and Block Admission Cancellation
06 November
Notice of Results and Investor Presentation
27 October
Holding(s) in Company
13 October
Holding(s) in Company
02 October
Holding(s) in Company
15 September
Change of website
15 September
Change of Name
06 September
Result of AGM
06 September
AGM Statement
01 September
Update on proposed Share Reorganisation
31 August
Proposed Share Reorganisation Timetable and Change of Name
22 August
Directorate Change
17 August
Board Appointment
15 August
Director/PDMR Shareholding
14 August
Posting of Annual Report and confirmation of AGM
03 August
Final Results
27 July
Notice of Final Results & Investor Presentation
26 July
Holding(s) in Company
06 June
Holding(s) in Company
05 June
Holding(s) in Company
02 June
Holding(s) in Company
22 May
Holding(s) in Company
10 May
Block Listing Six Monthly Return
09 May
Director/PDMR Shareholding
21 April
TR1 - Standard form for notification of major holdings
19 April
TR1: - Standard form for notification of major holdings
17 April
Trading update
22 March
Block Listing Six Monthly Review
22 March
TR1: Standard form for notification of major holdings
06 March
TR1- Standard form for notification of major holdings
27 January
TR-1: Standard form for notification of major holdings
27 January
Director/PDMR Shareholding
18 January
Trading update
16 January
TR-1: Standard form for notification of major holdings
06 January
US expansion update
03 January
TR-1: Standard form for notification of major holdings

2022

13 December
TR-1: Standard form for notification of major holdings
30 November
TR-1: Standard form for notification of major holdings
25 November
Receipt of deferred consideration
24 November
Interim Results FY22/23
18 November
Holding(s) In Company
15 November
Confirmation of Interim Results
14 November
Partnership agreement with Nutrigenomics Software Provider
08 November
Share Incentive Plan
26 October
Result of AGM
26 October
AGM Statement and Notice of Results
11 October
Scientific Director to present at FIDHC
05 October
Positive WHO data received for VISITECT® CD4 test
27 September
Posting of Annual Report and confirmation of AGM
21 September
TR-1: Standard form for notification of major holdings
16 September
Purchase of Shares by Directors
13 September
Investor presentation and Confirmation of AGM
12 September
Annual Results FY21/22
02 September
Holding(s) in Company
31 August
Change of preliminary results date
12 August
Change of preliminary results date and investor presentation
08 August
Notice of Results and Investor Presentation
06 August
Holding(s) in Company
03 August
Completion of Sale of the CD4 Business
11 July
Payment received
04 July
CD4 Head Of Terms Agreement
10 June
Grant of share incentives
08 June
PDMR/Director Dealing
06 June
Result of General Meeting And Total Voting Rights
01 June
Result of Open Offer
11 May
Holding(s) in Company
06 May
Investor presentation
06 May
Placing, Subscription, Open Offer & Notice of General Meeting
07 April
Trading Update
11 March
Update on validation under CTDA legislation
07 March
Result of General Meeting
07 March
Confirmation of Sale of Alva manufacturing business
01 March
Result of Open Offer
18 February
Investor Meeting
11 February
Fundraising to raise gross proceeds of up to £7.0 million
11 February
Sale of Alva manufacturing business
10 February
Speculation regarding a potential fundraise
03 February
CE-Mark for self-test for VISITECT® COVID-19 antigen test
31 January
Speculation regarding a potential fundraise
19 January
Directorate Change
10 January
Confirmation of detection of Omicron variant

2021

14 December
Confirmation of detection of Omicron variant
10 December
DHSC contract update
25 November
Interim Results for the six months ended 30 September 2021
05 November
Notice of Results: Investor Presentation
03 November
Update on new CTDA Regulations
01 November
Exercise of Options and Total Voting Rights
01 November
Exclusive Partnership with DAM Health and initial LFT order
19 October
Exercise of Options and Total Voting Rights
15 September
Result of AGM
15 September
AGM Statement
06 September
VISITECT® COVID-19 antigen test self-test submission update
30 July
Posting of Annual Report and Accounts and Notice of AGM
27 July
AbC-19TM test to monitor vaccine responses to variants of concern
13 July
Final Results for the year ended 31 March 2021
13 July
Directorate Change
09 July
AbC-19TM rapid antibody test performance evaluation
02 July
FDA submission for Emergency Use Authorization
16 June
Notice of results - Investor presentation
15 June
Statement re. Media Comment
08 June
Regulatory progress for VISITECT® COVID-19 Antigen test
07 June
Progress update
01 June
Positive study data for Mologic COVID-19 lateral flow antigen test
05 May
Further positive data for Mologic COVID-19 lateral flow antigen test
30 April
Exercise of Options and Total Voting Rights
30 April
Launch of VISITECT® COVID-19 Antigen & Update
23 April
Exercise of Options and Total Voting Rights
19 April
Director/PDMR Shareholding
31 March
Director/PDMR Shareholding, Exercise of Options and Total Voting Rights
26 March
Exercise of Options and Total Voting Rights
22 March
CE-Mark of Mologic COVID-19 lateral flow antigen test
19 March
Exercise of Options and Total Voting Rights
15 March
Statement re. Government press release
15 March
UK Public Sector Contract disclosure
08 March
Grant of Options
02 March
Contract with Screen4 for COVID-19 antibody laboratory-based testing service
24 February
UK-RTC statement on AbC-19TM rapid antibody test
19 February
Director/PDMR Shareholding, Exercise of Options and Total Voting Rights
18 February
Director/PDMR Shareholding, Exercise of Options and Total Voting Rights
16 February
AbC-19TM rapid antibody test performance data
15 February
Director/PDMR Shareholding, Exercise of Options and Total Voting Rights
11 February
UK Government manufacturing contract. Board appointment & trading update
11 February
Directorate Change
08 February
Statement re. media comment
02 February
Exercise of Options and Total Voting Rights
28 January
Exercise of Options and Total Voting Rights
26 January
Update re AbC-19TM Rapid Test & Launch of COVID-19 antibody laboratory-based testing service
26 January
Launch of COVID-19 antibody laboratory-based testing service
22 January
Exercise of Options and Total Voting Rights
11 January
Exercise of Options and Total Voting Rights

2020

29 December
Update re AbC-19TM Rapid Test (pdf)
24 December
Mologic CE Mark Rapid Antigen Test (pdf)
11 December
Exercise of Options and Total Voting Rights (pdf)
07 December
Exercise of Options and Total Voting Rights (pdf)
02 December
Director PDMR Dealing (pdf)
30 November
Exercise of Options and Total Voting Rights (pdf)
30 November
Interim Results for the six months ended 30 September 2020 (pdf)
23 November
Exercise of Options and Total Voting Rights (pdf)
17 November
UK-RTC update (pdf)
16 November
Holding(s) in Company (pdf)
16 November
Holding(s) in Company (pdf)
13 November
Exercise of Options and Total Voting Rights (pdf)
12 November
UK-RTC statement (pdf)
12 November
Response to media comment (pdf)
11 November
Investor presentation – Q&A Update (pdf)
09 November
Exercise of Options and Total Voting Rights (pdf)
06 November
Exercise of Options and Total Voting Rights (pdf)
03 November
Chinese approval for self-test use of Food Detective® test (pdf)
30 October
Exercise of Options and Total Voting Rights (pdf)
29 October
Holding(s) in Company (pdf)
28 October
Trading update and notice of interim results (pdf)
20 October
Notice of Trading Update and Investor Presentation (pdf)
20 October
Exercise of Options and Total Voting Rights (pdf)
19 October
UK-RTC contract for the Supply of Goods (pdf)
14 October
Exercise of Options and Total Voting Rights (pdf)
09 October
Exercise of Options and Total Voting Rights (pdf)
07 October
UK Government contract for UK-Rapid Test Consortium (pdf)
06 October
Holding(s) in Company (pdf)
06 October
UK Government contract for UK-Rapid Test Consortium (pdf)
02 October
Preliminary report published by Ulster University (pdf)
29 September
Investor Presentation (pdf)
15 September
Exercise of Options and Total Voting Rights (pdf)
15 September
TR-1 Standard form for notification of major holdings (pdf)
14 September
Exercise of Options and Total Voting Rights (pdf)
10 September
Holding(s) in Company (pdf)
07 September
Statement regarding Share Price Movement (pdf)
07 September
Completion of self-test usability study for AbC-19™ Rapid test (pdf)
03 September
CE-Mark for Mologic COVID-19 antibody test (pdf)
01 September
Exercise of Options and Total Voting Rights (pdf)
26 August
Result of Annual General Meeting (pdf)
26 August
Exercise of Options and Total Voting Rights (pdf)
24 August
Exercise of Options and Total Voting Rights (pdf)
21 August
WHO Prequalification received (pdf)
30 July
Update on progress of UK-Rapid Test Consortium (pdf)
24 July
Exercise of options and Total Voting Rights (pdf)
23 July
Notice of AGM and posting of Annual Report (pdf)
20 July
Investor presentation (pdf)
14 July
Final Results for the year ended 31 March 2020 (pdf)
10 July
Result of General Meeting (pdf)
10 July
Notice of Results (pdf)
08 July
Result of Open Offer – full take up (pdf)
02 July
Approval for sale in India (pdf)
29 June
Update on progress of UK-Rapid Test Consortium (pdf)
22 June
Publication of Shareholder Circular (pdf)
22 June
Investor presentation (pdf)
19 June
Fundraising to raise gross proceeds of up to £11 million (pdf)
09 June
Trading Update (pdf)
03 June
Update on progress of UK-Rapid Test Consortium (pdf)
01 June
Holding(s) in Company (pdf)
27 May
Statement regarding share price movement (pdf)
22 May
Exercise of options TVR and issue of equity (pdf)
07 May
Exercise of Options and Total Voting Rights (pdf)
04 May
Exercise of Options and Total Voting Rights (pdf)
30 April
Exercise of Options and Total Voting Rights (pdf)
29 April
Holding(s) in Company (pdf)
28 April
Holding(s) in Company (pdf)
28 April
VISITECT® CD4 Advanced Disease Supply Agreement with Clinton Health Access Initiative, Inc_ (pdf)
27 April
CE-Mark of COVID-19 ELISA antibody test (pdf)
20 April
Material Transfer Agreement with Mologic on COVID-19 antibody test (pdf)
20 April
Holding(s) in Company (pdf)
16 April
Holding(s) in Company (pdf)
16 April
Holding(s) in Company (pdf)
14 April
Holding(s) in Company (pdf)
09 April
Memorandum of Understanding COVID-19 Consortium (pdf)
06 April
VISITECT® CD4 Advanced Disease evaluation in Malawi, Zimbabwe and the Democratic Republic of Congo (pdf)
06 April
Holding(s) in Company (pdf)
02 April
Trading Update (pdf)
02 April
Chinese Approval for Food Detective test (pdf)
24 January
Grant of options (pdf)
17 January
Nigerian Ministry of Health approval for VISITECT® CD4 350 test (pdf)

2019

02 December
Interim Results for the six months ended 30 September 2019 (pdf)
02 December
Nigerian order for VISITECT® CD4 (pdf)
25 November
Update on Allergy test menu (pdf)
21 November
Investor results briefing (pdf)
22 October
Result of Annual General Meeting (pdf)
22 October
Trading Update and Notice of Interim Results (pdf)
15 October
Holding(s) in Company (pdf)
14 October
Holding(s) in Company (pdf)
14 October
Holding(s) in Company (pdf)
11 October
Holding(s) in Company (pdf)
10 October
Result of General Meeting (pdf)
27 September
Notice of AGM and Posting of Annual Report (pdf)
23 September
Placing & Subscription and Notice of General Meeting (pdf)
23 September
Final Results for the Year Ended 31 March 2019 (pdf)
16 September
Update on VISITECT® CD4 Advanced Disease (pdf)
10 September
Second Purchase Order for Chinese Food Detective® test (pdf)
20 August
First Purchase Order for VISITECT® CD4 Advanced Disease Test (pdf)
16 August
Announcement of Results, trading update and Nigerian order for VISITECT® CD4 (pdf)
06 June
Announcement of Results (pdf)
05 June
Holding(s) in Company (pdf)
03 June
Holding(s) in Company (pdf)
22 May
Subscription to raise c.£635,000 (pdf)
17 April
Trading Update (pdf)
18 March
CE-Mark for VISITECT® CD4 Advanced Disease test (pdf)
06 March
VISITECT® CD4 update (pdf)
01 March
Board Appointment (pdf)
29 January
VISITECT® CD4 Advanced Disease test update (pdf)

2018

10 December
Directorate Change (pdf)
03 December
Interim results for six months ended 30 Sep 2018 (pdf)
19 October
Holding(s) in Company (pdf)
10 October
Trading Update and Notice of Interim Results (pdf)
27 September
Allergy CE-Mark and first Purchase Order (pdf)
14 September
Result of Annual General Meeting (pdf)
10 September
Holding(s) in Company (pdf)
06 August
Final Results for the year ended 31 March 2018 (pdf)
06 August
VISITECT® CD4 Advanced Disease Development Update (pdf)
18 July
VISITECT® CD4 commercialisa (pdf)
02 July
Notice of Results (pdf)
28 June
Disposal of infectious disease business for up to £2.175m (pdf)
21 May
VISITECT® CD4 development update (pdf)
08 May
Allersys CE Mark (pdf)
02 May
Closure of Omega Diagnostics GmbH (pdf)
24 April
PDMR Dealing (pdf)
24 April
Holding(s) in Company (pdf)
23 April
Holding(s) in Company (pdf)
23 April
Director_PDMR Shareholding 2 (pdf)
23 April
Holding(s) in Company (pdf)
23 April
Director_PDMR Shareholding (pdf)
20 April
Allersys Distribution Agreement (pdf)
10 April
Strategic Review of operations and Trading Update (pdf)
10 April
Price Monitoring Extension (pdf)
12 January
Holding(s) in Company (pdf)

2017

21 December
Allersys® CE-Mark (pdf)
14 December
CEO succession (pdf)
29 November
VISITECT CD4 CE-Mark (pdf)
01 November
Change of Registered Office (pdf)
23 October
Trading Update and Notice of Interim Results (pdf)
16 October
US Supply Agreement (pdf)
10 October
Holding(s) in Company (pdf)
05 September
Exercise of Options and Total Voting Rights (pdf)
29 August
Result of Annual General Meeting (pdf)
18 July
Result of General Meeting (pdf)
17 July
Result of Open Offer (pdf)
06 July
Sale and leaseback of the building owned by Omega GmbH (pdf)
30 June
Result of Proposed Fundraising (pdf)
30 June
Proposed Fundraising (pdf)
30 June
Final Results for the year ended 31 March 2017 (pdf)
25 April
Trading Update and Notice of Results (pdf)
21 April
Holding(s) in Company (pdf)
27 March
VISITECT® Malaria CE-Mark and successful Indian FDA inspection (pdf)
07 March
Holding(s) in Company (pdf)
27 February
Holding(s) in Company (pdf)
27 January
Update on discussions with Immunodiagnostic Systems Holdings plc (pdf)
11 January
ISO accreditation for manufacturing facility in Pune, India (pdf)

2016

24 November
Holding(s) in Company (pdf)
17 October
Trading Update and Notice of Interim Results (pdf)
10 August
Result of Annual General Meeting (pdf)
02 August
R&D Grant Funding (pdf)
04 July
Holding(s) in Company (pdf)
01 July
Holding(s) in Company (pdf)
27 June
Final results for the year ended 31 March 2016 (pdf)
09 June
Holding(s) in Company (pdf)
21 April
Trading Update and Notice of Results (pdf)
08 February
Holding(s) in Company (pdf)

Latest Share Price

Investor News

Sign up for Investor Alerts